Apoptosis

, Volume 10, Issue 2, pp 267–275 | Cite as

On the role of galectin-3 in cancer apoptosis

Article

Abstract

Galectin-3, a member of the β-galactoside-binding gene family, is a multifunctional protein implicated in a variety of biological functions, including tumor cell adhesion, proliferation, differentiation, angiogenesis, cancer progression and metastasis. Recent studies revealed that intracellular galectin-3 exhibits the activity to suppress drug induced apoptosis and anoikis (apoptosis induced by the loss of cell anchorage) that contribute to cell survival. Resistance to apoptosis is essential for cancer cell survival and plays a role in tumor progression. Conversely, it was recently shown that tumor cells’ secreted galectin-3 induces T-cells’ apoptosis, thus playing a role in the immune escape mechanism during tumor progression through induction of apoptosis of cancer-infiltrating T-cells. This review summarizes recent evidences on the role of galectin-3 as an anti-apoptotic and/or pro-apoptotic factor in various cell types and discusses the recent understanding of the molecular mechanisms of galectin-3 role in apoptosis. We also suggest potential directions for further analyses of this multifunctional protein.

Keywords

apoptosis extracellular galectin-3 phosphorylation T-cell 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barondes SH, Castronovo V, Cooper DN, et al. Galectins: A family of animal beta-galactoside-binding lectins. Cell 1994; 76: 597–598.PubMedGoogle Scholar
  2. 2.
    Hirabayashi J, Hashidate T, Arata Y, et alOligosaccharide specificity of galectins: A search by frontal affinity chromatography. Biochim Biophys Acta 2002; 1572: 232–254.PubMedGoogle Scholar
  3. 3.
    Sacchettini JC, Baum LG, Brewer CF. Multivalent protein-carbohydrate interactions. A new paradigm for supermolecular assembly and signal transduction. Biochemistry 2001; 40: 3009–3015.PubMedGoogle Scholar
  4. 4.
    Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994; 269: 20807–20810.PubMedGoogle Scholar
  5. 5.
    Gong HC, Honjo Y, Nangia-Makker P, et al. The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res 1999; 59: 6239–6245.PubMedGoogle Scholar
  6. 6.
    Moutsatsos IK, Wade M, Schindler M, Wang JL. Endogenous lectins from cultured cells: Nuclear localization of carbohydrate-binding protein 35 in proliferating 3T3 fibroblasts. Proc Natl Acad Sci USA 1987; 84: 6452–6456.PubMedGoogle Scholar
  7. 7.
    Hughes RC. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta 1999; 1473: 172–185.PubMedGoogle Scholar
  8. 8.
    Rabinovich GA, Baum LG, Tinari N, et al. Galectins and their ligands: Amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 2002; 23: 313–320.PubMedGoogle Scholar
  9. 9.
    Liu FT, Patterson RJ, Wang JL. Intracellular functions of galectins. Biochim Biophys Acta 2002; 1572: 263–273.PubMedGoogle Scholar
  10. 10.
    Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis. Glycoconj J 2004; 19: 543–549.CrossRefPubMedGoogle Scholar
  11. 11.
    Lotan R, Ito H, Yasui W, Yokozaki H, Lotan D, Tahara E. Expression of a 31-kDa lactoside-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int J Cancer 1994; 56: 474–480.PubMedGoogle Scholar
  12. 12.
    Xu XC, el-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 1995; 147: 815–822.PubMedGoogle Scholar
  13. 13.
    Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 1996; 93: 6737–6742.PubMedGoogle Scholar
  14. 14.
    Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: A novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 1997; 57: 5272–5276.PubMedGoogle Scholar
  15. 15.
    Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 1999; 59: 4148–4154.PubMedGoogle Scholar
  16. 16.
    Yu F, Finley RL Jr, Raz A, Kim HR. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem 2002; 277: 15819–15827.PubMedGoogle Scholar
  17. 17.
    Hsu DK, Yang RY, Pan Z, et al. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol 2000; 156: 1073–1083.PubMedGoogle Scholar
  18. 18.
    Fukumori T, Takenaka Y, Yoshii T, et al. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res 2003; 63: 8302–8311.PubMedGoogle Scholar
  19. 19.
    Moon BK, Lee YJ, Battle P, Jessup JM, Raz A, Kim HR. Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: Implication of galectin-3 function during metastasis. Am J Pathol 2001; 159: 1055–1060.PubMedGoogle Scholar
  20. 20.
    Hanada M, Aimé-Sempé C, Sato T, Reed JC. Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J Biol Chem 1995; 270: 11962–11969.PubMedGoogle Scholar
  21. 21.
    Yang RY, Hill PN, Hsu DK, Liu FT. Role of the carboxyl-terminal lectin domain in self-association of galectin-3. Biochemistry 1998; 37: 4086–4092.PubMedGoogle Scholar
  22. 22.
    Joo HG, Goedegebuure PS, Sadanaga N, Nagoshi M, von Bernstorff W, Eberlein TJ. Expression and function of galectin-3, a beta-galactoside-binding protein in activated T lymphocytes. J Leukoc Biol 2001; 69: 555–564.PubMedGoogle Scholar
  23. 23.
    Hsu DK, Hammes SR, Kuwabara I, Greene WC, Liu FT. Human T lymphotropic virus-I infection of human T lymphocytes induces expression of the beta-galactoside-binding lectin, galectin-3. Am J Pathol 1996; 148: 1661–1670.PubMedGoogle Scholar
  24. 24.
    Dumic J, Lauc G, Flogel M. Expression of galectin-3 in cells exposed to stress-roles of jun and NF-kappaB. Cell Physiol Biochem 2000; 10: 149–158.PubMedGoogle Scholar
  25. 25.
    Liu L, Sakai T, Sano N, Fukui K. Nucling mediates apoptosis by inhibiting expression of galectin-3 through interference with nuclear factor kappaB signalling. Biochem J 2004; 380: 31–41.PubMedGoogle Scholar
  26. 26.
    Kuklinski S, Vladimirova V, Waha A, Kamata H, Pesheva P, Probstmeier R. Expression of galectin-3 in neuronally differentiating PC12 cells is regulated both via Ras/MAPK-dependent and -independent signalling pathways. J Neurochem 2003; 87: 1112–1124.PubMedGoogle Scholar
  27. 27.
    Stock M, Schafer H, Stricker S, Gross G, Mundlos S, Otto F. Expression of galectin-3 in skeletal tissues is controlled by Runx2. J Biol Chem 2003; 278: 17360–17367.PubMedGoogle Scholar
  28. 28.
    Davidson PJ, Davis MJ, Patterson RJ, Ripoche MA, Poirier F, Wang JL. Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 2002; 12: 329–337.PubMedGoogle Scholar
  29. 29.
    Takenaka Y, Fukumori T, Yoshii T, et al. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 2004; 24: 4395–4406.PubMedGoogle Scholar
  30. 30.
    Califice S, Castronovo V, Bracke M, Van Den Brule F. Dual activities of galectin-3 in human prostate cancer: Tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 2004; 23: 7527–7536.PubMedGoogle Scholar
  31. 31.
    Honjo Y, Inohara H, Akahani S, et al. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 2000; 6: 4635–4640.PubMedGoogle Scholar
  32. 32.
    Huflejt ME, Turck CW, Lindstedt R, Barondes SH, Leffler H. L-29, a soluble lactose-binding lectin, is phosphorylated on serine 6 and serine 12 in vivo and by casein kinase I. J Biol Chem 1993; 268: 26712–26718.Google Scholar
  33. 33.
    Mazurek N, Conklin J, Byrd JC, Raz A, Bresalier RS. Phosphorylation of the beta-galactoside-binding protein galectin-3 modulates binding to its ligands. J Biol Chem 2000; 275: 36311–36315.PubMedGoogle Scholar
  34. 34.
    Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002; 277: 6852–6857.PubMedGoogle Scholar
  35. 35.
    Ito T, Deng X, Carr B, May WS. Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 1997; 272: 11671–11673.PubMedGoogle Scholar
  36. 36.
    Breitschopf K, Haendeler J, Malchow P, Zeiher AM, Dimmeler S. Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: Molecular characterization of the involved signaling pathway. Mol Cell Biol 2000; 20: 1886–1896.PubMedGoogle Scholar
  37. 37.
    Burlacu A. Regulation of apoptosis by Bcl-2 family proteins. J Cell Mol Med 2003; 7: 249–257.PubMedGoogle Scholar
  38. 38.
    Vito P, Pellegrini L, Guiet C, D’Adamio L. Cloning of AIP1, a novel protein that associates with the apoptosis-linked gene ALG-2 in a Ca2+-dependent reaction. J Biol Chem 1999; 274: 1533–1540.PubMedGoogle Scholar
  39. 39.
    Missotten M, Nichols A, Rieger K, Sadoul R. Alix, a novel mouse protein undergoing calcium-dependent interaction with the apoptosis-linked-gene 2 (ALG-2) protein. Cell Death Differ 1999; 6: 124–129.PubMedGoogle Scholar
  40. 40.
    Sperandio S, Poksay K, De Belle I, et al. Paraptosis: Mediation by MAP kinases and inhibition by AIP-1/Alix. Cell Death Differ 2004; 11: 1066–1075.PubMedGoogle Scholar
  41. 41.
    Garin J, Diez R, Kieffer S, et al. The phagosome proteome: Insight into phagosome functions. J Cell Biol 2001; 152: 165–180.PubMedGoogle Scholar
  42. 42.
    Elad-Sfadia G, Haklai R, Balan E, Kloog Y. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem 2004; 279: 34922–34930.PubMedGoogle Scholar
  43. 43.
    Paron I, Scaloni A, Pines A, et al. Nuclear localization of Galectin-3 in transformed thyroid cells: A role in transcriptional regulation. Biochem Biophys Res Commun 2003; 302: 545–553.PubMedGoogle Scholar
  44. 44.
    Lin HM, Pestell RG, Raz A, Kim HR. Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene 2002; 21: 8001–8010.PubMedGoogle Scholar
  45. 45.
    Wang JL, Gray RM, Haudek KC, Patterson RJ. Nucleocytoplasmic lectins. Biochim Biophys Acta 2004; 1673: 75–93.PubMedGoogle Scholar
  46. 46.
    Menon RP, Hughes RC. Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex. Eur J Biochem 1999; 264: 569–576.PubMedGoogle Scholar
  47. 47.
    Matarrese P, Fusco O, Tinari N, et al. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 2000; 85: 545–554.PubMedGoogle Scholar
  48. 48.
    Inohara H, Akahani S, Raz A. Galectin-3 stimulates cell proliferation. Exp Cell Res 1998; 245: 294–302.PubMedGoogle Scholar
  49. 49.
    Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T cells mediated by galectin-1. Nature 1995; 378: 736–739.PubMedGoogle Scholar
  50. 50.
    Perillo NL, Uittenbogaart CH, Nguyen JT, Baum LG. Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes. J Exp Med 1997; 185: 1851–1858.PubMedGoogle Scholar
  51. 51.
    Ellerhorst J, Nguyen T, Cooper DN, et al. Induction of differentiation and apoptosis in the prostate cancer cell line LNCaP by sodium butyrate and galectin-1. Int J Oncol 1999; 14: 225–232.PubMedGoogle Scholar
  52. 52.
    Blaser C, Kaufmann M, Müller C, et al. Beta-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur J Immunol 1998; 28: 2311–2319.PubMedGoogle Scholar
  53. 53.
    Novelli F, Allione A, Wells V, Forni G, Mallucci L. Negative cell cycle control of human T cells by beta-galactoside binding protein (beta GBP): Induction of programmed cell death in leukaemic cells. J Cell Physiol 1999; 178: 102–108.PubMedGoogle Scholar
  54. 54.
    Pace KE, Lee C, Stewart PL, Baum LG. Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J Immunol 1999; 163: 3801–3811.PubMedGoogle Scholar
  55. 55.
    Pace KE, Hahn HP, Pang M, Nguyen JT, Baum LG. CD7 delivers a pro-apoptotic signal during galectin-1-induced T cell death. J Immunol 2000; 165: 2331–2334.PubMedGoogle Scholar
  56. 56.
    Nguyen JT, Evans DP, Galvan M, et al. CD45 modulates galectin-1-induced T cell death: Regulation by expression of core 2 O-glycans. J Immunol 2001; 167: 5697–5707.PubMedGoogle Scholar
  57. 57.
    Fukumori T, Takenaka Y, Oka N, et al. Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Res 2004; 64: 3376–3379.PubMedGoogle Scholar
  58. 58.
    Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17: 1675–1687.PubMedGoogle Scholar
  59. 59.
    Barnhart BC, Alappat EC, Peter ME. The CD95 type I/type II model. Semin Immunol 2003; 15: 185–193.CrossRefPubMedGoogle Scholar
  60. 60.
    Demetriou M, Granovsky M, Quaggin S, Dennis JW. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 2001; 409: 733–739.PubMedGoogle Scholar
  61. 61.
    Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 2000; 6: 1389–1393.PubMedGoogle Scholar
  62. 62.
    Hughes RC. Galectins as modulators of cell adhesion. Biochimie 2001; 83: 667–676.PubMedGoogle Scholar
  63. 63.
    Dong S, Hughes RC. Galectin-3 stimulates uptake of extracellular Ca2 + in human Jurkat T-cells. FEBS Lett 1996; 395: 165–169.PubMedGoogle Scholar
  64. 64.
    Rosenberg I, Cherayil BJ, Isselbacher KJ, Pillai S. Mac-2-binding glycoproteins. Putative ligands for a cytosolic beta-galactoside lectin. J Biol Chem 1991; 266: 18731-18736.PubMedGoogle Scholar
  65. 65.
    Furtak V, Hatcher F, Ochieng J. Galectin-3 mediates the endocytosis of beta-1 integrins by breast carcinoma cells. Biochem Biophys Res Commun 2001; 289: 845–850.PubMedGoogle Scholar
  66. 66.
    Ohannesian DW, Lotan D, Thomas P, et al. Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res 1995; 55: 2191–2199.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  1. 1.Tumor Progression and Metastasis Program, Karmanos Cancer InstituteWayne State UniversityDetroitUSA

Personalised recommendations